FeesSafety
Pluang+

Moderna stock surges 545% in 2026, investors face choice to take profits or hold for pipeline growth.

Market News
06 Oct 2026, 22:03 WIB
24/7 Wall Street
View Source
Bullish
Moderna stock surges 545% in 2026, investors face choice to take profits or hold for pipeline growth.

Moderna's stock has soared 545% year-to-date, driven by its mRNA technology and a promising oncology pipeline including a personalized cancer vaccine. The company now joins the NASDAQ 100, increasing its visibility and institutional interest. Despite strong gains, investors must weigh locking in profits against the risks and potential of Moderna's developing treatments. The stock's rapid rise outpaces peers like BioNTech and Pfizer, highlighting the need for careful portfolio management.

As of Oct 07, 2026 02:21 WIB, Moderna (MRNA) trades at USD 189.95, close to its 52-week high of USD 203.46 but down 6.53% on the day, contrasting with Pfizer (PFE) which is near its 52-week high at USD 27.48 and up 0.26%. BioNTech (BNTX) remains below its 52-week peak at USD 96.22, down 1.45%, while Moderna's market cap of $81.13B is significantly smaller than Pfizer's $156.23B. On Pluang, Moderna sees a strong buy interest at 76%, compared to Pfizer's 29% buy activity.

More News (MRNA)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App